Semaglutide NYC: How Telehealth Care Works in New York

How It Works

How Semaglutide Care Works for a New York Patient

Semaglutide in NYC runs on video, and the only part that has to happen in person is the blood draw. A clinician licensed to treat patients located in New York evaluates you, orders bloodwork, reads the results, and decides from there whether a GLP-1 medication is appropriate for you at all.

The sequence for a New Yorker looks like this:

A telehealth consult. History, current medications, weight history, and the conditions that change the answer, such as thyroid disease, pancreatitis, or gallbladder problems.
Labs you draw near home. The prescriber places the order; you walk into a Labcorp or Quest patient service center and have blood drawn. Both run patient service centers across the five boroughs, Long Island, and the Hudson Valley, so for most New Yorkers this is rarely more than a subway ride.
Results in a dashboard. Your panel lands in a results dashboard you can read yourself, alongside the prescriber's interpretation, rather than being summarized at you over the phone.
A decision, written down. A documented reason to treat or not to treat. A clinic that cannot produce that reasoning is selling a product rather than practicing medicine.

Protocol Health runs medical weight loss in that order for New York patients. One clarification, because it matters when you are deciding who to see: Protocol Health's only in-person clinic is in Scarsdale, New York. There is no Protocol Health office in Manhattan, Brooklyn, Queens, the Bronx, Staten Island or on Long Island. New York City patients are treated by video.

Book a weight loss consultation

Not a Controlled Substance

Semaglutide Is Not a Controlled Substance, and That Changes the New York Rules

Semaglutide is not a controlled substance under federal or New York law, and that single fact removes the biggest regulatory hurdle people expect. New York does restrict controlled substances: 10 NYCRR 80.63(d)(1) bars prescribing one before an in-person medical evaluation, with 80.63(e) excepting telehealth conducted consistently with DEA rules, and that is the framework shaping telehealth care for testosterone and for stimulants. It does not reach semaglutide at all, because semaglutide is not scheduled federally or under New York Public Health Law 3306. Neither is tirzepatide.

What does govern a semaglutide prescription in New York is the licensing question, and it turns on where the patient is rather than where the clinic is. A clinician must hold a license to treat a patient physically located in New York. A practice on Park Avenue can be the wrong prescriber for you; a practice with no New York office can be the right one. One New York license also covers the whole state, so a video visit from Astoria, Riverdale, or Poughkeepsie sits under exactly the same authority as an exam room in Westchester.

The practical consequence for a New Yorker is that the search is not for a nearby waiting room. It is for a licensed prescriber who will look at your labs before writing anything.

Compounded vs Brand

Compounded Semaglutide and the Brand Products Are Not the Same Thing

Compounded semaglutide is not an FDA-approved drug, and any NYC clinic that blurs that line is doing you a disservice. The FDA states the position plainly: compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness, or quality before they are marketed.

The brand semaglutide products went through the FDA approval process. A compounded preparation did not, and it was not the product studied in the trials those brands ran. Nothing established about an approved product transfers automatically to a compounded one. Both can be dispensed, and a provider should be able to tell you without hedging which one you are being offered and from which pharmacy. They are not on the same legal footing: since the semaglutide shortage ended, a 503A pharmacy may compound for an individual patient on a prescription, but may not regularly compound what the FDA treats as essentially a copy of a commercially available product unless the prescriber documents a change that makes a significant difference for that patient. Ask which applies to you.

This is also the question that separates NYC med spas from each other most sharply. Ask it first.

The Evidence

What the Published Semaglutide and Tirzepatide Trials Measured

The weight-change figures attached to semaglutide come from large randomized trials of the brand products, and they are worth reading as published results rather than as a forecast for you.

In STEP 1, published in the New England Journal of Medicine in 2021, 1,961 adults with overweight or obesity and without diabetes were randomized to 68 weeks of once-weekly subcutaneous semaglutide at 2.4 mg or placebo, both with lifestyle intervention. Mean body weight change from baseline to week 68 was -14.9% with semaglutide and -2.4% with placebo. Nausea and diarrhea were the most common adverse events, typically transient and mild to moderate.

In SURMOUNT-1, published in the same journal in 2022, 2,539 adults with obesity, or overweight with at least one weight-related complication and without diabetes, received once-weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks. Mean weight change at week 72 was -15.0%, -19.5%, and -20.9% across the three doses against -3.1% with placebo.

Two limits on those numbers, stated up front. Those milligram figures describe what the published trials administered under protocol, not a dose anyone should take; the prescribing clinician sets dose against your labs and history. And both trials studied the FDA-approved brand products, so they do not establish results for a compounded preparation.

Safety

Who Should Not Take Semaglutide

Semaglutide carries a boxed warning, and it rules some people out before any other conversation happens. The FDA-approved semaglutide labeling reports that in rodents semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and that it is unknown whether it causes them in humans. The labeling contraindicates semaglutide in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. That contraindication is about the molecule, not the brand, and Protocol Health applies it to every semaglutide prescription it writes, compounded or not.

A family history here means what it says. A grandparent's thyroid cancer is a reason to say so during the consult, not a detail to leave out because you want the prescription.

Beyond the boxed warning, gastrointestinal effects are the common ones, and pancreatitis, gallbladder disease, and, in patients with type 2 diabetes, diabetic retinopathy complications are among the matters a prescriber screens for. This page does not substitute for that screening.

Choosing a Provider

What to Ask a Semaglutide Provider in New York

The useful questions for a NYC GLP-1 clinic are not about price. Four of them will tell you in about ninety seconds how a clinic actually operates.

Who writes the prescription, and are they licensed in New York? A name and a license, not a brand.
Am I being offered a compounded preparation or an FDA-approved product, and from which pharmacy? A direct answer, with the pharmacy named.
What labs do you run before prescribing, and will I see the results myself? A named panel, and your own access to the results. A clinic that prescribes with no bloodwork at all is a reasonable thing to walk away from, including us.
What happens when side effects start? A reachable clinician, not a support inbox.

A disclosure, since this page recommends asking hard questions and we are one of the parties being asked: Protocol Health sells GLP-1 weight-loss care, including semaglutide and tirzepatide, and has a commercial interest in your deciding to start treatment. Weigh this page accordingly, and ask us the same four questions.

Westchester readers, and New York City readers who would rather be seen in person, have a page of their own: medical weight loss in Westchester covers the in-person side of the same care. Everyone else in New York is treated by video. No outcome is guaranteed, and semaglutide is not appropriate for everyone. The treating clinician decides whether a GLP-1 medication is appropriate for you, in which form, and at what dose, against your labs and history. This page sets no dose and gives no individual advice. Start with the two-minute health quiz.

FAQ

Frequently Asked Questions

Is semaglutide a controlled substance in New York?

No. Semaglutide is not scheduled under federal controlled-substance law or under New York Public Health Law 3306, and neither is tirzepatide. New York's requirement for an in-person evaluation before prescribing a controlled substance, 10 NYCRR 80.63(d)(1), therefore does not apply to a semaglutide prescription. It still requires a prescription from a licensed clinician.

Can you get semaglutide through telehealth in NYC?

Yes, when the prescriber holds a license to treat a patient located in New York. The patient's location governs rather than the clinic's street address, and one New York license covers the whole state. That makes video care the practical route for the five boroughs, Long Island, and the Hudson Valley.

Does Protocol Health have a clinic in Manhattan or anywhere in New York City?

No. Protocol Health's only in-person clinic is in Scarsdale, New York. There is no Protocol Health office in Manhattan, Brooklyn, Queens, the Bronx, or Staten Island. New York City patients are treated by video, with labs drawn locally.

Where do New York patients get labs drawn for semaglutide?

The prescriber places the lab order and you have blood drawn at a Labcorp or Quest patient service center near you. Results are returned to a dashboard you can read yourself, alongside the clinician's interpretation. No travel to Westchester is required for the draw.

Is compounded semaglutide FDA-approved?

No. The FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before they are marketed. The FDA-approved brand semaglutide products are separate products, and the trials run on them did not study a compounded preparation.

Who should not take semaglutide?

Semaglutide carries a boxed warning for thyroid C-cell tumors seen in rodents, and the labeling contraindicates it in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Tell the prescriber about any family thyroid cancer during the consult.

Explore

Related at Protocol Health